26 July 2022 | News
Biogénesis Bagó joins Korean company FVC for the construction of the site
Image credit: shutterstock
Argentina-based Biogénesis Bagó, an international biotechnology company focused on animal health and global leader in Foot and Mouth Disease (FMD) vaccines, has announced its consortium with the South Korean company FVC for the construction of a world class site that will produce up to 100 million doses of FMD vaccine per year.
The new manufacturing site will be located in the Korean town of Osong, 110 km from the capital Seoul and is under construction, expected to be completed by 2023. The project will require an investment of around $50 million and is being coordinated by a high-skilled task force of Biogénesis Bagó´s professionals with previous experience in leading tech transfer process in Asia.
The strategic partnership will provide South Korea with advanced technologies that will allow it to supply their internal market with safe, world-class FMD vaccines, creating more affordable solutions for local livestock producers and helping to protect the country's sanitary status while collaborating with local health authority Animal and Plant Quarantine Agency (APQA) through research and development.